Precision BioSciences’ (DTIL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Precision BioSciences (NASDAQ:DTIL) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $60.00 target price on the stock.

Separately, BMO Capital Markets upgraded shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a report on Friday.

Precision BioSciences Trading Up 26.7 %

Shares of DTIL stock opened at $5.70 on Friday. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $19.43. The firm has a market cap of $43.72 million, a PE ratio of 95.02 and a beta of 1.41. The company has a 50-day moving average of $6.09 and a two-hundred day moving average of $8.25. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Hedge Funds Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC grew its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.